Tag: Immunotherapy
Racial, Ethnic Disparities Seen for Subcutaneous Allergen Immunotherapy
Black, Hispanic patients have lower rates of initiation than White patients
Blinatumomab Safe, Efficacious for Infants With KMT2A-Rearranged Leukemia
No toxic effects seen meeting definition of primary end point; profile of toxic effects consistent with that reported in older patients
Anti-PD-1 More Effective With Normal Vitamin D Levels in Melanoma
Significantly higher response rate and longer progression-free survival seen for patients with normal vitamin D
AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer
Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation
Interferon Alfa-2b Effective for Low-Grade Lymphomatoid Granulomatosis
61 percent of patients had complete response to interferon alfa-2b; patients with high-grade disease showed expected response to chemo
Neoadjuvant, Adjuvant Pembrolizumab Beneficial in Resectable Melanoma
Event-free survival longer for those receiving neoadjuvant and adjuvant pembrolizumab versus adjuvant pembrolizumab only
Targeted Therapies Seem Beneficial for Immune Checkpoint Inhibitor-Related Myotoxicity
Myotoxicity-related fatality rate 3.4 percent after institution of screening coupled with active ventilation, treatment
PD-1 Inhibitor Treatment Effective for Localized Mismatch Repair-Deficient CRC
84.9 percent of 73 patients achieved objective response, including 23.3 percent with complete response
Oral Immunotherapy With Boiled Then Roasted Peanuts Feasible
Sequential approach is feasible and safe for peanut allergy, with very low frequency of rescue epinephrine use
QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma
Quality of life favored the pembrolizumab arm versus standard-of-care arm receiving ipilimumab, high-dose interferon α 2b
